Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Tango Therapeutics (TNGX) EBIT Margin (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of EBIT Margin data on record, last reported at 29.5% in Q3 2025.

  • For Q3 2025, EBIT Margin rose 31278.0% year-over-year to 29.5%; the TTM value through Dec 2025 reached 170.6%, up 17549.0%, while the annual FY2025 figure was 178.39%, 16769.0% up from the prior year.
  • EBIT Margin reached 29.5% in Q3 2025 per TNGX's latest filing, up from 1287.87% in the prior quarter.
  • Across five years, EBIT Margin topped out at 29.5% in Q3 2025 and bottomed at 1287.87% in Q2 2025.
  • Average EBIT Margin over 5 years is 439.3%, with a median of 432.41% recorded in 2022.
  • The widest YoY moves for EBIT Margin: up 31278bps in 2025, down -113918bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 384.6% in 2021, then fell by -24bps to 476.79% in 2022, then plummeted by -35bps to 644.69% in 2023, then crashed by -54bps to 993.68% in 2024, then soared by 103bps to 29.5% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 29.5% in Q3 2025, 1287.87% in Q2 2025, and 788.76% in Q1 2025.